The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update
机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease, Beijing, China[2]Shanghai Children’s Medical Center, Shanghai, China[3]Institute of Hematologyand Blood Disease Hospital, Chinese Academy of Medical Sciencesand Peking Union Medical College, National Clinical Research Centerfor Hematologic Disease, Tianjin, China[4]First Affiliated Hospital of ZhejiangUniversity, Hangzhou, China[5]The First Affiliated Hospital of Xinjiang MedicalUniversity, Urumqi, China[6]The First Affiliated Hospital of Guangxi MedicalUniversity, Guilin, China[7]General Hospital of PLA (People’s Liberation Armyof China), Beijing, China[8]Nanfang Hospital of Southern Medical University,Guangzhou, China[9]West China Hospital, Sichuan University, Chengdu, China四川大学华西医院[10]Peking University First Hospital, Beijing, China[11]Affiliated Cancer Hospitalof Zhengzhou University, Henan Cancer Hospital, Zhengzhou, China河南省肿瘤医院[12]TheFirst Affiliated Hospital of University of Science and Technology of China, Hefei,China[13]The First Affiliated Hospital of Soochow Hospital, National ClinicalResearch Center for Hematologic Disease, Suzhou, China[14]Changhai Hospitalof Shanghai, Naval Medical University, Shanghai, China[15]Xinqiao Hospital,Army Military Medical University, Chongqing, China[16]Peking Union MedicalCollege Hospital, Beijing, China[17]Peking-Tsinghua Center for Life Sciences,Beijing, China
The consensus recommendations in 2018 from The Chinese Society of Hematology (CSH) on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation (allo-HSCT) facilitated the standardization of clinical practices of allo-HSCT in China and progressive integration with the world. There have been new developments since the initial publication. To integrate recent developments and further improve the consensus, a panel of experts from the CSH recently updated the consensus recommendations, which are summarized as follows: (1) there is a new algorithm for selecting appropriate donors for allo-HSCT candidates. Haploidentical donors (HIDs) are the preferred donor choice over matched sibling donors (MSDs) for patients with high-risk leukemia or elderly patients with young offspring donors in experienced centers. This replaces the previous algorithm for donor selection, which favored MSDs over HIDs. (2) Patients with refractory/relapsed lymphoblastic malignancies are now encouraged to undergo salvage treatment with novel immunotherapies prior to HSCT. (3) The consensus has been updated to reflect additional evidence for the application of allo-HSCT in specific groups of patients with hematological malignancies (intermediate-risk acute myeloid leukemia (AML), favorable-risk AML with positive minimal residual disease, and standard-risk acute lymphoblastic leukemia). (4) The consensus has been updated to reflect additional evidence for the application of HSCT in patients with nonmalignant diseases, such as severe aplastic anemia and inherited diseases. (5) The consensus has been updated to reflect additional evidence for the administration of anti-thymocyte globulin, granulocyte colony-stimulating factors and post-transplantation cyclophosphamide in HID-HSCT.
基金：
National Key Research and Development Plan of China [2017YFA0104500, 2017YFA0105500]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81621001, 81930004, 81730004, 81970113]
第一作者机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease, Beijing, China
通讯作者：
通讯机构：[1]Peking University People’s Hospital, Peking University Institute of Hematology,Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation,National Clinical Research Center for Hematologic Disease, Beijing, China[17]Peking-Tsinghua Center for Life Sciences,Beijing, China
推荐引用方式(GB/T 7714)：
Zhang Xiao-hui,Chen Jing,Han Ming-Zhe,et al.The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update[J].JOURNAL OF HEMATOLOGY & ONCOLOGY.2021,14(1):doi:10.1186/s13045-021-01159-2.
APA：
Zhang, Xiao-hui,Chen, Jing,Han, Ming-Zhe,Huang, He,Jiang, Er-lie...&Huang, Xiao-jun.(2021).The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update.JOURNAL OF HEMATOLOGY & ONCOLOGY,14,(1)
MLA：
Zhang, Xiao-hui,et al."The consensus from The Chinese Society of Hematology on indications, conditioning regimens and donor selection for allogeneic hematopoietic stem cell transplantation: 2021 update".JOURNAL OF HEMATOLOGY & ONCOLOGY 14..1(2021)
医学